An alpha-blocker, which relaxes the smooth muscles in the bladder neck, and prostate gland, thereby improve urinary flow. (R Rosen, 2007) First-line treatment for the management of uncomplicated, moderate-to-severe, lower urinary tract symptoms associated with benign prostatic hyperplasia. (Roehrborn, 2007) Effective in alleviating lower urinary tract symptoms and patients’ quality of life. (Mostafa Elhilali, 2006) Provides a suitable pharmacokinetic profile for a once-daily administration. (P Ahtoy, 2002) Associated with a lower rate of symptomatic postural hypotension and less hemodynamic impact than terazosin. (Hn Tang, 2017) Offers a rapid onset of action that leads to improvements in urine flow rate and lower urinary tract symptoms. (Roehrborn, 2007) Efficacious in alleviating lower urinary tract symptoms with a decreased potential for cardiovascular adverse effects as postural hypotension. (Lowe, 2004) Shows better vasodilatory tolerability than the older immediate-release formulation. (McVary, 2006) Provides effective relief from benign prostatic hyperplasia and maintains long-term clinical benefits. (P van Kerrebroec, 2002) Appears to be a promising alternative to prostatectomy in patients who require surgery and in patients requiring symptomatic relief while awaiting surgery.(M I Wilde, 1993)